GX McLeod, SM Hammer - Annals of internal medicine, 1992 - Am Coll Physicians Since the licensure of zidovudine in 1987, an intensive clinical research effort
has established the drug's efficacy in the prevention of disease progression in
asymptomatic and mildly symptomatic HIV-infected persons and has ... Cited by 99 - Related articles - BL Direct - All 3 versions
MD Zaretsky - Genetica, 1995 - Springer Malcolm D. Zaretsky Department of Molecular and Cell Biology, University of
California, Berkeley, CA 94720, USA Address for correspondence." Dept. of
Molecular and Cell Biology, Life Sciences Addition, University of ... Cited by 8 - Related articles - BL Direct - All 5 versions
MS Hirsch, RT D'Aquila - New England Journal of Medicine, 1993 - content.nejm.org Much is known about the replication of the human immunodeficiency virus type 1
(HIV-1) from the time of cell attachment to the release of mature virions
(Figure 1), and drugs that interfere with many of the steps in HIV ... Cited by 123 - Related articles - BL Direct - All 5 versions
- ►nih.gov [PDF] P Toltzis, T Mourton, T Magnuson - Antimicrobial agents and chemotherapy, 1993 - Am Soc Microbiol Page 1. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1993, p. 1610-1613
0066-4804/93/081610-04$02.00/0 Copyright X 1993, American Society for Microbiology ... Cited by 29 - Related articles - BL Direct - All 8 versions
MA Fischl, DD Richman, DM Causey, MH … - JAMA, 1989 - Am Med Assoc We examined the long-term safety and efficacy of zidovudine therapy in 229
subjects with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
who previously participated in a placebo-controlled study of zidovudine. ... Cited by 159 - Related articles - All 3 versions
MA Sande, CC Carpenter, CG Cobbs, KK … - Jama, 1993 - Am Med Assoc This document summarizes recommendations from a state-of-the-art conference
convened to evaluate the role of nucleoside analogue reverse transcriptase
inhibitors in the treatment of human immunodeficiency virus (HIV) ... Cited by 108 - Related articles - BL Direct - All 3 versions
MC McNeely, R Yarchoan, S Broder, TJ … - Journal of the American Academy of Dermatology, 1989 - Elsevier We describe a distinctive mucocutaneous eruption that occurred in 14 of 20 (70%)
patients with human immunodeficiency virus infection while they were being
treated with a new therapeutic agent, 2' 3'-dideoxycytidine. A ... Cited by 37 - Related articles - All 4 versions
MA Fischl, CB Parker, C Pettinelli, M … - New England Journal of Medicine, 1990 - content.nejm.org BACKGROUND. The initially tested dose of zidovudine for the treatment of
patients with advanced disease caused by the human immunodeficiency virus type 1
(HIV) was 1500 mg. Although this dose is effective, it is associated with ... Cited by 205 - Related articles - All 4 versions
JD Hamilton, PM Hartigan, MS Simberkoff - J Med, 1992 - rethinkingaids.com Vol.326 Na 7 EARLY VS. 1.ЛТК ZIDOVUDINE IK HIV INFECTION HAMILTON FT Al. 43<)
group and 7 in the late-therapy group) who did not mct't the eligibility
criteria in minor way». The: exclu- sion of thrse 11 patients does not ... Cited by 235 - Related articles - All 8 versions
